Clinical Trial Update: Augmenting Response to Entecavir With Peginterferon a-2a for the Treatment of HBeAg-positive Chronic Hepatitis B [Phase 4]

View source ↗

Summary

A Phase 4 study assessing whether adding peginterferon alfa-2a to entecavir improves response in HBeAg-positive chronic hepatitis B; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Baraclude (entecavir)
• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Foundation for Liver Research | Conditions: Chronic Hepatitis B | Phase 4 | Status: COMPLETED